Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ann Steward LaCasce, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, Byrd JC, Blum KA, LaCasce AS, Hsi ED, Liu YT, Scott DW, Hurd D, Ruppert AS, Hernandez-Ilizaliturri F, Leonard JP, Cheson BD. Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. Am J Hematol. 2020 06; 95(6):583-593. PMID: 32170769.
    Citations:    
  2. Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 Mar 10; 4(5):858-867. PMID: 32126141.
    Citations:    
  3. LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, Advani R. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. Br J Haematol. 2020 May; 189(3):e86-e90. PMID: 32048731.
    Citations:    
  4. Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, Herrera AF, Dahi P, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Bsat J, Patel SS, Ritz J, Rodig SJ, Shipp MA, Chen YB, Joyce RM. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 Jan 14; 4(1):122-126. PMID: 31917843.
    Citations:    
  5. Singer S, Tan SY, Dewan AK, Davids M, LaCasce AS, Treon SP, LeBoeuf NR. Cutaneous Eruptions from Ibrutinib Resembling EGFR Inhibitor-Induced Dermatologic Adverse Events. J Am Acad Dermatol. 2019 Dec 20. PMID: 31870917.
    Citations:    
  6. Allen PB, LaCasce AS. Evidence-Based Minireview: What is the optimal timing of anti-PD-1 antibodies in relapsed classical Hodgkin lymphoma? Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):249-251. PMID: 31808863.
    Citations:    
  7. Merryman RW, LaCasce A. Novel agents and immune invasion in Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):243-248. PMID: 31808827.
    Citations:    
  8. Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, Montegaard J, Patterson V, Jacobson CA, Jacobsen ED, LaCasce AS, Arnason JE, Armand P, Fisher DC, Brown JR, Davids MS. Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32. PMID: 31723987.
    Citations:    
  9. Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019 10 10; 134(15):1238-1246. PMID: 31331918.
    Citations:    
  10. Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Aug; 6(8):e419-e428. PMID: 31208944.
    Citations:    
  11. Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, Neuberg D, Takvorian RW, Hochberg EP, Bello CM. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. 2019 08 15; 134(7):606-613. PMID: 31186274.
    Citations:    
  12. LaCasce AS. Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease. Hematol Oncol. 2019 Jun; 37 Suppl 1:87-91. PMID: 31187532.
    Citations:    
  13. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw. 2019 06 01; 17(6):650-661. PMID: 31200358.
    Citations:    
  14. LaCasce A, Graff S, Gao J, Close J, Boulmay B. Preparing Fellows for Graduation: Perspectives on Career Guidance. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:609-614. PMID: 31099656.
    Citations:    
  15. Dewan AK, Gupta S, Bach DQ, Jadeja S, Granter S, LaCasce A, Joyce R, Davids MS, Huang V, LeBoeuf NR. Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition. JAAD Case Rep. 2019 May; 5(5):401-405. PMID: 31049381.
    Citations:    
  16. Poorvu PD, Frazier AL, Feraco AM, Manley PE, Ginsburg ES, Laufer MR, LaCasce AS, Diller LR, Partridge AH. Cancer Treatment-Related Infertility: A Critical Review of the Evidence. JNCI Cancer Spectr. 2019 Mar; 3(1):pkz008. PMID: 31360893.
    Citations:    
  17. Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29. PMID: 30952672.
    Citations:    
  18. Crombie JL, LaCasce AS. Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders. Front Oncol. 2019; 9:109. PMID: 30899698.
    Citations:    
  19. Kim AI, Goergen H, Engert A, LaCasce AS, Maranda L, Barton B, Borchmann S. Suicide in European Hodgkin Lymphoma Patients. Hemasphere. 2019 Apr; 3(2):e183. PMID: 31723822.
    Citations:    
  20. Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Crysler OV, Gupta N, Gustafson C, Hall A, Johung KL, Klopp A, LaCasce AS, Lin C, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Ratner L, Rizza S, Rudek MA, Sanchez J, Taylor J, Tomlinson B, Wang CJ, Yendamuri S, Dwyer MA, Freedman-Cass DA. AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 02; 17(2):171-189. PMID: 30787130.
    Citations:    
  21. Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018 Dec; 5(12):e609-e617. PMID: 30501868.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  22. Crombie JL, LaCasce AS. Current considerations in AYA Hodgkin lymphoma. Br J Haematol. 2019 01; 184(1):72-81. PMID: 30460695.
    Citations:    Fields:    
  23. Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. N Engl J Med. 2018 Nov 01; 379(18):1711-1721. PMID: 30380386.
    Citations:    Fields:    Translation:HumansCellsCTClinical Trials
  24. Davids MS, Kim HT, Yu L, De Maeyer G, McDonough M, Vartanov AR, Langey R, Fernandes SM, Hellman JM, Francoeur K, Arnason J, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR. Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. Leuk Lymphoma. 2019 05; 60(5):1312-1315. PMID: 30322319.
    Citations:    Fields:    
  25. Merryman RW, LaCasce A. Reply to H.J.A. Adams et al. J Clin Oncol. 2018 Nov 10; 36(32):3274-3275. PMID: 30222482.
    Citations:    Fields:    
  26. Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Gupta N, Johung KL, Klopp A, LaCasce AS, Lin C, Makarova-Rusher OV, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Palella F, Ratner L, Rizza S, Rudek MA, Taylor J, Tomlinson B, Wang CJ, Dwyer MA, Freedman-Cass DA. Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 08; 16(8):986-1017. PMID: 30099375.
    Citations:    Fields:    
  27. Ozuah NW, Marcus KJ, LaCasce AS, Billett AL. Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma. J Pediatr Hematol Oncol. 2018 08; 40(6):e338-e342. PMID: 29293187.
    Citations:    Fields:    
  28. Craig JW, Mina MJ, Crombie JL, LaCasce AS, Weinstock DM, Pinkus GS, Pozdnyakova O. Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. PLoS One. 2018; 13(7):e0199708. PMID: 30020951.
    Citations:    Fields:    Translation:Humans
  29. Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, Smith GL, Abou Yehia Z, Qiao W, Wogan CF, Akhtari M, Mawlawi O, Medeiros LJ, Chuang HH, Martin-Doyle W, Armand P, LaCasce AS, Oki Y, Fanale M, Westin J, Neelapu S, Nastoupil L. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018 06 12; 2(11):1334-1343. PMID: 29895624.
    Citations:    
  30. Merryman RW, LaCasce AS. Response-Adapted Therapy in Aggressive Lymphoma: Not Yet Ready for Clinical Care. J Clin Oncol. 2018 07 10; 36(20):2009-2011. PMID: 29787359.
    Citations:    Fields:    
  31. Hogan LE, Hanhauser E, Hobbs KS, Palmer CD, Robles Y, Jost S, LaCasce AS, Abramson J, Hamdan A, Marty FM, Kuritzkes DR, Henrich TJ. Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation. PLoS One. 2018; 13(5):e0197298. PMID: 29746555.
    Citations:    Fields:    Translation:HumansCells
  32. LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, Advani R. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018 07 05; 132(1):40-48. PMID: 29703778.
    Citations: 4     Fields:    
  33. Canellos GP, LaCasce AS. Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med. 2018 04 19; 378(16):1560. PMID: 29671468.
    Citations:    Fields:    Translation:Humans
  34. Sun L, Li S, El-Jawahri A, Armand P, Dey BR, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, McAfee SL, Spitzer TR, Chen YB, DeFilipp Z. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis. Oncologist. 2018 05; 23(5):624-630. PMID: 29284757.
    Citations: 1     Fields:    
  35. Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018 03 15; 131(11):1183-1194. PMID: 29229594.
    Citations: 5     Fields:    
  36. Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017 12; 179(5):739-747. PMID: 29082519.
    Citations: 5     Fields:    Translation:Humans
  37. Kahn JM, Ozuah NW, Dunleavy K, Henderson TO, Kelly K, LaCasce A. Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes. Blood Adv. 2017 Oct 10; 1(22):1945-1958. PMID: 29296842.
    Citations: 3     
  38. LaCasce AS, Flores EJ, Goldstein RH, Sohani AR. Case 25-2017. N Engl J Med. 2017 Aug 17; 377(7):677-688. PMID: 28813220.
    Citations:    Fields:    Translation:HumansCells
  39. Henrich TJ, Hobbs KS, Hanhauser E, Scully E, Hogan LE, Robles YP, Leadabrand KS, Marty FM, Palmer CD, Jost S, Körner C, Li JZ, Gandhi RT, Hamdan A, Abramson J, LaCasce AS, Kuritzkes DR. Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. J Infect Dis. 2017 07 15; 216(2):254-262. PMID: 28838149.
    Citations: 5     Fields:    Translation:HumansCells
  40. Ozuah NW, Dahmoush HM, Grant FD, Lehmann LE, LaCasce AS, Billett AL, Margossian SP. Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation. Pediatr Blood Cancer. 2018 Jan; 65(1). PMID: 28696028.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  41. Ozuah NW, LaCasce AS. How to Approach a Patient With Limited Stage Hodgkin Lymphoma Who Remains PET Positive at the End of Chemotherapy: Radiation Therapy? Clin Lymphoma Myeloma Leuk. 2017 11; 17(11):710-715. PMID: 28711575.
    Citations:    Fields:    Translation:Humans
  42. Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, Friedberg JW, van der Jagt RH, LaCasce AS, Joyce R, Ganjoo KN, Bartlett NL, Lemieux B, VanderWalde A, Herst J, Szer J, Bar MH, Cabanillas F, Dodds AJ, Montgomery PG, Pressnail B, Ellis T, Smith MR, Leonard JP. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. Br J Haematol. 2017 07; 178(2):250-256. PMID: 28419413.
    Citations: 1     Fields:    Translation:Humans
  43. Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, Armand P, Rodig SJ, Shipp MA. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017 06 08; 129(23):3071-3073. PMID: 28356247.
    Citations: 22     Fields:    Translation:Humans
  44. Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. J Natl Compr Canc Netw. 2017 03; 15(3):293-311. PMID: 28275031.
    Citations: 8     Fields:    Translation:Humans
  45. Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, Bosworth A, Francisco L, He J, Bansal A, Morgan EA, Lacasce AS, Freedman AS, Fisher DC, Jacobsen E, Armand P, Alyea EP, Koreth J, Ho V, Soiffer RJ, Antin JH, Ritz J, Nikiforow S, Forman SJ, Michor F, Neuberg D, Bhatia R, Bhatia S, Ebert BL. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605. PMID: 28068180.
    Citations: 18     Fields:    Translation:HumansCells
  46. Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan; 35(1):24-31. PMID: 28034071.
    Citations: 4     Fields:    Translation:Humans
  47. Zhou Z, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, Vanderplas A, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson MM, Zelenetz AD, Niland J, Friedberg JW, Winter JN. High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. J Natl Compr Canc Netw. 2016 10; 14(10):1274-1281. PMID: 27697981.
    Citations:    Fields:    Translation:Humans
  48. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. J Natl Compr Canc Netw. 2016 09; 14(9):1067-79. PMID: 27587620.
    Citations: 7     Fields:    Translation:Humans
  49. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. PMID: 27479034.
    Citations: 13     Fields:    
  50. Kumar A, Burger IA, Zhang Z, Drill EN, Migliacci JC, Ng A, LaCasce A, Wall D, Witzig TE, Ristow K, Yahalom J, Moskowitz CH, Zelenetz AD. Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. Haematologica. 2016 10; 101(10):1237-1243. PMID: 27390360.
    Citations: 2     Fields:    Translation:Humans
  51. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. PMID: 27070704.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  52. Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016 06 10; 34(17):2020-7. PMID: 27069074.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  53. Janssen A, Shaw T, Bradbury L, Moujaber T, Nørrelykke AM, Zerillo JA, LaCasce A, Co JP, Robinson T, Starr A, Harnett P. A mixed methods approach to developing and evaluating oncology trainee education around minimization of adverse events and improved patient quality and safety. BMC Med Educ. 2016 Mar 12; 16:91. PMID: 26968519.
    Citations:    Fields:    Translation:Humans
  54. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Diffuse Large B-Cell Lymphoma Version 1.2016. J Natl Compr Canc Netw. 2016 Feb; 14(2):196-231. PMID: 26850490.
    Citations: 7     Fields:    Translation:Humans
  55. Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, LaCasce AS, Jacobson C, Davids MS, Brown JR, Weng L, Wilkins J, Faham M, Freedman AS, Joyce R, Jacobsen ED. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016 Apr; 173(1):89-95. PMID: 26729345.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  56. Flinn IW, Bartlett NL, Blum KA, Ardeshna KM, LaCasce AS, Flowers CR, Shustov AR, Thress KS, Mitchell P, Zheng F, Skolnik JM, Friedberg JW. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Eur J Cancer. 2016 Feb; 54:11-17. PMID: 26707592.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  57. Odejide OO, Cronin AM, Earle CC, LaCasce AS, Abel GA. Hospice Use Among Patients With Lymphoma: Impact of Disease Aggressiveness and Curability. J Natl Cancer Inst. 2016 Jan; 108(1). PMID: 26438575.
    Citations: 7     Fields:    Translation:Humans
  58. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw. 2015 Mar; 13(3):326-62. PMID: 25736010.
    Citations: 8     Fields:    Translation:Humans
  59. Yenikomshian MA, Guignard AP, Haguinet F, LaCasce AS, Skarin AT, Trahey A, Karner P, Duh MS. The epidemiology of herpes zoster and its complications in Medicare cancer patients. BMC Infect Dis. 2015 Feb 27; 15:106. PMID: 25888128.
    Citations: 2     Fields:    Translation:HumansCells
  60. Tirumani SH, LaCasce AS, Jacene HA. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma. PET Clin. 2015 Apr; 10(2):207-25. PMID: 25829087.
    Citations: 4     Fields:    Translation:Humans
  61. Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015 Apr 01; 121(7):1032-9. PMID: 25492236.
    Citations: 4     Fields:    Translation:Humans
  62. Jacobson C, LaCasce A. How I treat Burkitt lymphoma in adults. Blood. 2014 Nov 06; 124(19):2913-20. PMID: 25258344.
    Citations: 10     Fields:    Translation:Humans
  63. Chen YB, Batchelor T, Li S, Hochberg E, Brezina M, Jones S, Del Rio C, Curtis M, Ballen KK, Barnes J, Chi AS, Dietrich J, Driscoll J, Gertsner ER, Hochberg F, LaCasce AS, McAfee SL, Spitzer TR, Nayak L, Armand P. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer. 2015 Jan 15; 121(2):226-33. PMID: 25204639.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  64. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Netw. 2014 Sep; 12(9):1282-303. PMID: 25190696.
    Citations: 22     Fields:    Translation:Humans
  65. Jacobsen E, Pozdnyakova O, Redd R, Fisher DC, Dorfman DM, Dal Cin P, LaCasce A, Armand P, Hochberg E, Cote G, Shahsafaei A, Neuberg D, Brown JR, Freedman AS. Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Leuk Lymphoma. 2015 Apr; 56(4):993-8. PMID: 25012943.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  66. Morrison VA, Jung SH, Johnson J, LaCasce A, Blum KA, Bartlett NL, Pitcher BN, Cheson BD. Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma. 2015 Apr; 56(4):958-64. PMID: 24996441.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  67. Odejide OO, Cronin AM, Davidoff AJ, LaCasce AS, Abel GA. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma. 2015 Mar; 56(3):716-24. PMID: 24913508.
    Citations: 6     Fields:    Translation:Humans
  68. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw. 2014 Jun; 12(6):916-46. PMID: 24925202.
    Citations: 14     Fields:    Translation:Humans
  69. Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson MM, Nademanee AP, Niland JC, Rodig SJ, Rodriguez MA, Zelenetz AD, LaCasce AS. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer. 2014 Jul 01; 120(13):1993-9. PMID: 24706502.
    Citations: 3     Fields:    Translation:Humans
  70. Nikiforow S, Lacasce AS. Targeting Epstein-Barr virus-associated lymphomas. J Clin Oncol. 2014 Mar 10; 32(8):830-2. PMID: 24493729.
    Citations: 1     Fields:    Translation:HumansCells
  71. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 06; 123(6):837-42. PMID: 24264230.
    Citations: 87     Fields:    Translation:Humans
  72. Tirumani SH, Ramaiya NH, Weinblatt ME, Leibner HA, Creager MA, LaCasce AS. Large vessel vasculopathy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. Leuk Lymphoma. 2014 Jul; 55(7):1654-6. PMID: 24024473.
    Citations:    Fields:    Translation:HumansCells
  73. Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol. 2013 Nov; 163(4):487-95. PMID: 24111533.
    Citations: 4     Fields:    Translation:Humans
  74. Odejide OO, Cronin AM, DeAngelo DJ, Bernazzoli ZA, Jacobson JO, Rodig SJ, LaCasce AS, Mazeika TJ, Earles KD, Abel GA. Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist. Cancer. 2013 Oct 01; 119(19):3472-8. PMID: 23921812.
    Citations: 2     Fields:    Translation:HumansCells
  75. Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS, Abel GA, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Zelenetz AD, Gordon LI, Friedberg JW. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer. 2013 Oct 15; 119(20):3662-71. PMID: 23921646.
    Citations: 10     Fields:    Translation:Humans
  76. Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct; 163(1):123-6. PMID: 23795711.
    Citations: 19     Fields:    Translation:HumansCells
  77. Brown JR, Messmer B, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, LaCasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70. PMID: 23645694.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  78. Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM, Gallien S, Lin NH, Giguel FF, Lavoie L, Ho VT, Armand P, Soiffer RJ, Sagar M, Lacasce AS, Kuritzkes DR. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis. 2013 Jun 01; 207(11):1694-702. PMID: 23460751.
    Citations: 101     Fields:    Translation:HumansCells
  79. Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M. Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Netw. 2013 Mar 01; 11(3):257-72; quiz 273. PMID: 23486452.
    Citations: 14     Fields:    Translation:HumansCells
  80. Abou-Nassar KE, Vanderplas A, Friedberg JW, Abel GA, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby A, Gordon LI, Zelenetz AD, Kaminski M, Lacasce AS. Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Leuk Lymphoma. 2013 Oct; 54(10):2155-62. PMID: 23343180.
    Citations: 1     Fields:    Translation:Humans
  81. Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013 Mar; 160(5):608-17. PMID: 23278720.
    Citations: 10     Fields:    Translation:Humans
  82. Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA. Non-Hodgkin's Lymphomas, version 3.2012. J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1487-98. PMID: 23221787.
    Citations: 9     Fields:    Translation:Humans
  83. Barnes JA, Jacobsen E, Feng Y, Freedman A, Hochberg EP, LaCasce AS, Armand P, Joyce R, Sohani AR, Rodig SJ, Neuberg D, Fisher DC, Abramson JS. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica. 2013 Apr; 98(4):615-9. PMID: 23144193.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  84. Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma. 2012 Nov; 53(11):2143-50. PMID: 22421007.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  85. Lindsley RC, LaCasce AS. Biology of double-hit B-cell lymphomas. Curr Opin Hematol. 2012 Jul; 19(4):299-304. PMID: 22504522.
    Citations: 4     Fields:    Translation:Humans
  86. Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):e647-54. PMID: 22607911.
    Citations: 4     Fields:    Translation:Humans
  87. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 May 17; 119(20):4597-607. PMID: 22383795.
    Citations: 84     Fields:    Translation:HumansCTClinical Trials
  88. Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, LaCasce AS. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma. 2012 Jun; 53(6):1113-6. PMID: 22098406.
    Citations: 7     Fields:    Translation:HumansPHPublic Health
  89. LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012 Mar 01; 119(9):2093-9. PMID: 22234679.
    Citations: 15     Fields:    Translation:Humans
  90. Lane AA, Armand P, Feng Y, Neuberg DS, Abramson JS, Brown JR, Fisher DC, LaCasce AS, Jacobsen ED, McAfee SL, Spitzer TR, Freedman AS, Chen YB. Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma. 2012 Jun; 53(6):1130-6. PMID: 22132836.
    Citations: 3     Fields:    Translation:Humans
  91. Fox AM, Dosoretz AP, Mauch PM, Chen YH, Fisher DC, LaCasce AS, Freedman AS, Silver B, Ng AK. Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):277-83. PMID: 22019238.
    Citations: 8     Fields:    Translation:Humans
  92. Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012 Jun 01; 118(11):2944-51. PMID: 22006274.
    Citations: 14     Fields:    Translation:Humans
  93. Cote GM, Hochberg EP, Muzikansky A, Hochberg FH, Drappatz J, McAfee SL, Batchelor TT, LaCasce AS, Fisher DC, Abramson JS, Armand P, Chen YB. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012 Jan; 18(1):76-83. PMID: 21749848.
    Citations: 15     Fields:    Translation:Humans
  94. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2011 May; 9(5):484-560. PMID: 21550968.
    Citations: 15     Fields:    Translation:Humans
  95. Ng AK, LaCasce A, Travis LB. Long-term complications of lymphoma and its treatment. J Clin Oncol. 2011 May 10; 29(14):1885-92. PMID: 21483015.
    Citations: 21     Fields:    Translation:Humans
  96. Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, Fisher DC, Lacasce AS, Jacobsen ED, Armand P, Hasserjian RP, Werner L, Neuberg D, Brown JR. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011 May 01; 17(9):2977-86. PMID: 21402714.
    Citations: 42     Fields:    Translation:HumansCTClinical Trials
  97. Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011 May 19; 117(20):5314-20. PMID: 21355087.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  98. Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, Hochberg EP, Abramson JS. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011 Aug; 22(8):1859-64. PMID: 21339382.
    Citations: 31     Fields:    Translation:HumansPHPublic Health
  99. Abou-Nassar KE, Stevenson KE, Antin JH, McDermott K, Ho VT, Cutler CS, LaCasce AS, Jacobsen ED, Fisher DC, Soiffer RJ, Alyea EP, Koreth J, Freedman AS. (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant. 2011 Dec; 46(12):1503-9. PMID: 21258420.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  100. Shinagare AB, Ramaiya NH, O'Regan K, Jagannathan JP, Hornick JL, LaCasce AS. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol. 2011 Apr 10; 29(11):e297-300. PMID: 21245429.
    Citations: 2     Fields:    Translation:HumansCells
  101. Giardino AA, O'Regan K, Jagannathan JP, Elco C, Ramaiya N, Lacasce A. Richter's transformation of chronic lymphocytic leukemia. J Clin Oncol. 2011 Apr 01; 29(10):e274-6. PMID: 21220587.
    Citations: 2     Fields:    Translation:Humans
  102. Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, Lacasce A, Morrison J, Elstrom R, Ely S, Chadburn A, Cesarman E, Coleman M, Leonard JP. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 Feb 20; 29(6):690-7. PMID: 21189393.
    Citations: 66     Fields:    Translation:HumansCTClinical Trials
  103. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010 Dec; 11(12):1149-59. PMID: 21094089.
    Citations: 177     Fields:    Translation:HumansCellsCTClinical Trials
  104. Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, Toomey CE, Hochberg EP, Canellos GP, Abramson JS. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol. 2011 Apr; 22(4):910-915. PMID: 20952598.
    Citations: 24     Fields:    Translation:Humans
  105. Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011 Jan 13; 117(2):412-8. PMID: 20858859.
    Citations: 38     Fields:    Translation:Humans
  106. Jacobson CA, LaCasce AS. Lymphoma: risk and response after solid organ transplant. Oncology (Williston Park). 2010 Sep; 24(10):936-44. PMID: 21138175.
    Citations: 6     Fields:    Translation:Humans
  107. Lee AI, Zuckerman DS, Van den Abbeele AD, Aquino SL, Crowley D, Toomey C, Lacasce AS, Feng Y, Neuberg DS, Hochberg EP. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer. 2010 Aug 15; 116(16):3835-42. PMID: 20564135.
    Citations: 19     Fields:    Translation:Humans
  108. Furman RR, Martin P, Ruan J, Cheung YK, Vose JM, LaCasce AS, Elstrom R, Coleman M, Leonard JP. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 2010 Dec 01; 116(23):5432-9. PMID: 20665890.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  109. Punnoose LR, Roh JD, Hu S, Udell JA, Wagle N, Kirshenbaum JM, Lacasce AS. Cardiac presentation of anaplastic large-cell lymphoma. J Clin Oncol. 2010 Jul 01; 28(19):e314-6. PMID: 20516445.
    Citations:    Fields:    Translation:Humans
  110. Chen YB, Hochberg EP, Feng Y, Neuberg D, Rawal B, Motyckova G, Fisher DC, McAfee SL, Spitzer TR, Lacasce AS. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma. 2010 May; 51(5):789-96. PMID: 20367136.
    Citations: 1     Fields:    Translation:Humans
  111. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2010 Mar; 8(3):288-334. PMID: 20202462.
    Citations: 61     Fields:    Translation:Humans
  112. Canellos GP, Abramson JS, Fisher DC, LaCasce AS. Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol. 2010 Mar 20; 28(9):1611-5. PMID: 20159818.
    Citations: 11     Fields:    Translation:Humans
  113. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010 Apr 01; 115(13):2578-85. PMID: 19965662.
    Citations: 234     Fields:    Translation:HumansCTClinical Trials
  114. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20; 27(36):6101-8. PMID: 19917845.
    Citations: 50     Fields:    Translation:HumansCTClinical Trials
  115. Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma. 2009 Aug; 9(4):307-10. PMID: 19717381.
    Citations: 12     Fields:    Translation:Humans
  116. Lee AI, LaCasce AS. Nodular lymphocyte predominant Hodgkin lymphoma. Oncologist. 2009 Jul; 14(7):739-51. PMID: 19605845.
    Citations: 9     Fields:    Translation:HumansCells
  117. Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol. 2009 Nov; 20(11):1848-53. PMID: 19541793.
    Citations: 20     Fields:    Translation:Humans
  118. Faris JE, LaCasce AS. Primary mediastinal large B-cell lymphoma. Clin Adv Hematol Oncol. 2009 Feb; 7(2):125-33. PMID: 19367254.
    Citations: 3     Fields:    Translation:Humans
  119. Kho ME, Lepisto EM, Niland JC, Friedberg JW, Lacasce AS, Weeks JC. Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database. Cancer. 2008 Dec 01; 113(11):3209-12. PMID: 18855918.
    Citations: 3     Fields:    Translation:Humans
  120. Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008 Dec 10; 26(35):5767-74. PMID: 19001324.
    Citations: 41     Fields:    Translation:Humans
  121. Abramson JS, Barnes JA, Toomey CE, Jacobsen ED, Armand P, Takvorian T, Fisher DC, Reynolds H, Hochberg EP, LaCasce AS. Rituximab added to CODOX-M/IVAC is highly effective in HIV-negative and HIV-positive Burkitt lymphoma. Blood. 2008; 112:3595.
  122. LaCasce AS, Kho ME, Friedberg JW, Niland JC, Abel GA, Rodriguez MA, Czuczman MS, Millenson MM, Zelenetz AD, Weeks JC. Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol. 2008 Nov 01; 26(31):5107-12. PMID: 18768434.
    Citations: 19     Fields:    Translation:Humans
  123. Oton AB, Wang H, Leleu X, Melhem MF, George D, Lacasce A, Foon K, Ghobrial IM. Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma. 2008 Sep; 49(9):1738-44. PMID: 18798108.
    Citations: 11     Fields:    
  124. Brown JR, Neuberg D, Phillips K, Reynolds H, Silverstein J, Clark JC, Ash M, Thompson C, Fisher DC, Jacobsen E, LaCasce AS, Freedman AS. Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. Br J Haematol. 2008 Nov; 143(3):361-8. PMID: 18729853.
    Citations: 8     Fields:    Translation:Humans
  125. Chen YB, LaCasce AS. Enzastaurin. Expert Opin Investig Drugs. 2008 Jun; 17(6):939-44. PMID: 18491994.
    Citations: 20     Fields:    Translation:HumansCells
  126. Wilson WH, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Dunleavy K, Krivoshik AP, Xiong H, Chiu Y, O'Connor OA. A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. J Clin Oncol. 2008 May 20; 26(15_suppl):8511. PMID: 27950969.
    Citations:    
  127. LaCasce AS, Freedman AS. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma. Semin Hematol. 2008 Apr; 45(2):85-9. PMID: 18381102.
    Citations: 2     Fields:    Translation:Humans
  128. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008 Apr; 14(4):418-25. PMID: 18342784.
    Citations: 37     Fields:    Translation:Humans
  129. Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2008 Apr; 6(4):356-421. PMID: 18433606.
    Citations: 1     Fields:    Translation:Humans
  130. Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, LaCasce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD. Bendamustine in Patients with Rituximab-Refractory Indolent and Transformed non-Hodgkin's Lymphoma: Results from a Phase II Multicenter, Single-Agent Study. J Clin Oncol. 2008; 26(2):204-210.
  131. Ann S. LaCasce. Therapeutic uses of high dose methotrexate. 2008.
  132. Chandrajit P. Raut and Ann S. LaCasce. Lymphoma of the Small Bowel. Advanced Therapy in Surgical Oncology (Pollock, Curley, Ross, Perrier). 2008; 236-247.
  133. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2007 May 01; 25(13):1741-6. PMID: 17389337.
    Citations: 60     Fields:    Translation:HumansCTClinical Trials
  134. Rodig SJ, Savage KJ, LaCasce AS, Weng AP, Harris NL, Shipp MA, Hsi ED, Gascoyne RD, Kutok JL. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol. 2007 Jan; 31(1):106-12. PMID: 17197926.
    Citations: 13     Fields:    Translation:HumansCells
  135. Jacobsen E, LaCasce A. Update on the therapy of highly aggressive non-Hodgkin's lymphoma. Expert Opin Biol Ther. 2006 Jul; 6(7):699-708. PMID: 16805709.
    Citations:    Fields:    Translation:Humans
  136. LaCasce AS. Post-transplant lymphoproliferative disorders. Oncologist. 2006 Jun; 11(6):674-80. PMID: 16794246.
    Citations: 24     Fields:    Translation:Humans
  137. Zelenetz AD, Advani RH, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Kaminski MS, Lacasce AS, Nademanee A, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Mar; 4(3):258-310. PMID: 16507273.
    Citations: 6     Fields:    Translation:Humans
  138. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, Kurtin P, Pinkus GS, de Leval L, Harris NL, Savage KJ, Neuberg D, Habermann TM, Dalla-Favera R, Golub TR, Aster JC, Shipp MA. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005 Aug 15; 106(4):1392-9. PMID: 15870177.
    Citations: 54     Fields:    Translation:HumansCells
  139. Ann S. LaCasce, M. Dror Michaelson, George P. Canellos. Malignant Lymphoma of the Genitourinary Tract. Comprehensive Textbook of Genitourinary Oncology. Nicholas J. Vogelzang, Peter T. Scardino, William J. Shipley, Frans M. J, Debruyne, W. Marston Linehan, editors. 2005; 877-881.
  140. Gribben J, LaCasce A. . Clinical Manifestations, Staging and Treatment of Non-Hodgkins Lymphoma. Hoffman B, Benz E, Shattil S, Furie B, Cohen H, Silberstein L, McGlave P, editors. Hematology: Basics Principles and Practice. 2005; 1397-1419.
  141. LaCasce, A. Is Chemotherapy Alone a Viable Alternative for Early-Stage Hodgkin's Lymphoma?. Am J Onc Rev. 2005; 4(3):213-215.
  142. Lacasce A, Howard O, Lib S, Fisher D, Weng A, Neuberg D, Shipp M. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004 Apr; 45(4):761-7. PMID: 15160953.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  143. LaCasce A. 2004; 3:485-487. Neurologic toxicity and the role of radiotherapy in Burkitt leukemia and lymphoma. Am J Onc Rev. 2004; 3:485-487.
  144. LaCasce A. . . Diffuse large B-cell lymphoma and rituximab: is bcl-2 the key?. Am J Onc Rev. 2003; 2:592-593.
  145. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman AS. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999 Oct; 17(10):3128-35. PMID: 10506609.
    Citations: 22     Fields:    Translation:Humans
  146. LaCasce A, Neuberg D, Jasonava A, Friedberg JW, Freedman AS, Nadler LM, Stone RM. . Clonal karyotypic abnormalities after autologous bone marrow transplantation for non-Hodgkin's Lymphoma are common and not always associated with myelodysplastic syndrome. Blood. 1998; 10:344a.
  147. Johnson RC, Mayadas TN, Frenette PS, Mebius RE, Subramaniam M, Lacasce A, Hynes RO, Wagner DD. Blood cell dynamics in P-selectin-deficient mice. Blood. 1995 Aug 01; 86(3):1106-14. PMID: 7542495.
    Citations: 26     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
LaCasce's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (398)
Explore
_
Co-Authors (147)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.